Using Dose Titration to Resolve Diarrhea on Ozempic (semaglutide 0.5-2 mg)

What does the Ozempic label say about titration?

The injection schedule is stepwise. Start with 0.25 mg once weekly for 4 weeks; this is not a maintenance dose. Then move to 0.5 mg. If more glycemic control is needed, increase to 1 mg after at least 4 weeks on 0.5 mg, and to 2 mg after at least 4 weeks on 1 mg. The maximum is 2 mg weekly [1].

The intervals are minimums: the label says at least 4 weeks, so it does not set a maximum time at a dose [1]. It describes no separate rule for diarrhea, no step-down schedule and no instruction to extend a dose level until diarrhea resolves [1].

The label does say the majority of nausea, vomiting and/or diarrhea reports occurred during dose escalation [1].

How common is diarrhea at 0.5 mg, 1 mg and 2 mg?

In the label's pooled placebo-controlled trials in type 2 diabetes (262 placebo, 260 on 0.5 mg, 261 on 1 mg; mean 32.9 weeks), diarrhea occurred in 1.9% on placebo, 8.5% on 0.5 mg and 8.8% on 1 mg [1]. Any GI reaction occurred in 15.3%, 32.7% and 36.4%, and GI reasons led to discontinuation in 0.4%, 3.1% and 3.8% [1]. Severe GI reactions were 0% on placebo, 0.4% on 0.5 mg and 0.8% on 1 mg [1].

The 2 mg dose was compared with 1 mg in a 40-week trial of 959 patients treated with Ozempic 1 mg or 2 mg. Overall GI reactions were 34% on 2 mg versus 30.8% on 1 mg, with no new safety signals [1]. The label does not give a separate diarrhea rate for the 2 mg arm in that trial [1].

What should be watched during dose escalation?

One label warning is tied to dehydration from GI reactions. Postmarketing reports include acute kidney injury, sometimes requiring hemodialysis, and the majority occurred in people who had GI reactions such as nausea, vomiting or diarrhea. The label advises monitoring renal function in people with reactions that could lead to volume depletion, especially during initiation and escalation [1].

The label also says Ozempic is not recommended in patients with severe gastroparesis [1]. Postmarketing reports in the label include ileus, intestinal obstruction and severe constipation with fecal impaction [1].